Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

ALISO VIEJO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today reported financial results for the third quarter and nine months ended September 30, 2009. Results included a 13 percent increase in net revenues for the third quarter of 2009 as compared to the third quarter of 2008. Third quarter net revenue was $21.4 million, compared to $19.0 million for the same period in 2008. Net revenue for this year's first nine months was $68.3 million, a 32 percent increase over the prior year period.

Third quarter net revenue was reduced by a change in estimate of expected third-party payor reimbursements based upon their cash collection behavior over the past fifteen months. In addition, this new information was used to set the current period's third-party payor reimbursement rates, which also reduced third quarter 2009 revenue. The analysis of patient payor behavior patterns over the past fifteen months was used to determine the adequacy of the allowance for bad debts, which was increased in the 2009 third quarter.

Ron Andrews, Clarient Vice Chairman and Chief Executive Officer said, "Our business in terms of customer growth, case volumes, tests per case, menu expansion and market penetration continues to grow and indicates the potential for even stronger quarters ahead for Clarient.

"At the beginning of 2009, management identified the reduction of our bad debt and improvement of our billing and collections processes as a top priority. The third quarter's financials include new information gathered after the close of the quarter which allowe
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 According to a new market ... For Transgenic Crops (Corn, Soybean, Cotton and Others), Synthetic ... Share, Growth, Trends and Forecast, 2013 – 2019,”the global ... in 2012 and is expected to reach USD 28,694.1 ... from 2013 to 2019. , Demand for food ...
(Date:2/26/2015)... 26, 2015 Regis Technologies announced ... of oncology drug substances. , Regis Technologies is proud ... new Potent Compound Suite (PCS) for 2015. , Regis ... foot, cGMP facility in Morton Grove, Illinois. The PCS ... potent compounds up to about one kilogram per batch. ...
(Date:2/26/2015)... , Feb. 26, 2015 Tauriga Sciences, Inc. ... company with interests in the natural wellness sector and ... today that its products will be featured at the ... Partners, 27 th Annual Growth Stock Conference on ... at 1 Ritz Carlton Drive, Dana Point ...
(Date:2/26/2015)... Texas , Feb. 26, 2015   Lexicon Pharmaceuticals, ... Lexicon management will present at the Cowen 35 th ... 8:40 a.m. EST in Boston .  Lexicon ... and milestones. A webcast of the presentation will ... archived version of the presentation will be available at ...
Breaking Biology Technology:Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... Rhythm announced today the results of a Phase 1b ... for the treatment of diabetic gastroparesis. The trial demonstrated ... diabetic gastroparesis. The findings were presented at the Digestive ... The Phase 1b clinical trial was a randomized, double-blind, ...
... To become better healers, tissue engineering need a timely and ... already are or can become the tissue they need to ... that the stiffness, viscosity, and other mechanical properties of adult ... predict whether they will turn into bone, cartilage, or fat. ...
... New York, May 21, 2012 Elsevier,s Computers & ... on 3D Object Retrieval which will incorporate the Collage Authoring ... place winner of the 2011 Executable Paper Grand Challenge. The ... Eurographics 2012 on May 13, during the 3DOR Workshop. ...
Cached Biology Technology:Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis 2Physical properties predict stem cell outcome 2Physical properties predict stem cell outcome 3
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to ... biometrics technology is to ensure that an individual is who ... technology may make use of a person,s unique physical characteristics, ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... to botulinum neurotoxins, which are among the most potent ... a bacterium found in soil and food. In the ... with nerve transmission and disrupting the communication between the ... botulinum toxins leads to an often-fatal paralysis, which is ...
... that transplanting human stem cells into spinal cords of ... start of nerve cell damage typical of the disease ... into nerve cells that make substantial connections with existing ... also known as amyotrophic lateral sclerosis (ALS). The study ...
... Researchers at the University of Pennsylvania School of Medicine ... leukemia (AML). Several lines of evidence point to a ... took over the starship Enterprise in the original Star ... , "Tribbles had never been directly linked ...
Cached Biology News:Human stem cells delay start of Lou Gehrig's disease in rats 2Human stem cells delay start of Lou Gehrig's disease in rats 3'Tribbles' protein implicated in common and aggressive form of leukemia 2
... from E. coli is a ... also contains both 5'--3'and 3'--5' ... activity enables the enzyme to ... the DNA as starting points ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... thymus Description: Topoisomerase I relaxes both ... breakage and rejoining of phosphodiester bonds (1,2) . ... to be differentiated by a single nucleotide pair ... active in the absence of Mn 2+ ...
...
Biology Products: